Legend

Session Format

In Person

Livestreamed

On Demand

All times listed are Pacific Standard Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.

Type here to filter the list

Monday, Nov 13th
9:00 AM – 11:00 AM PT
(1052–1081) Immunological Complications of Medical Therapy Poster
Location: Poster Hall
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1052: Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking
Location: Poster Hall
Abstract Poster Presenter: Sokratis Apostolidis, MD – University of Pennsylvania
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1053: Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Location: Poster Hall
Abstract Poster Presenter: Denis Krutko, MD – University of Utah
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1054: Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
Location: Poster Hall
Abstract Poster Presenter: David Liew, MBBS, FRACP – Austin Health
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1055: Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
Location: Poster Hall
Abstract Poster Presenter: Vanissa Savarimuthu, -None- (she/her/hers) – McGill University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1056: Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
Location: Poster Hall
Abstract Poster Presenter: Alexandra Ladouceur, MD, PhD – McGill University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1057: Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Location: Poster Hall
Abstract Poster Presenter: Alexandra Ladouceur, MD, PhD – McGill University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1058: Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors
Location: Poster Hall
Abstract Poster Presenter: Alexandra Ladouceur, MD, PhD – McGill University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1059: Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data
Location: Poster Hall
Abstract Poster Presenter: Anne Bass, MD – Hospital for Special Surgery, Weill Cornell Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1060: Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Location: Poster Hall
Abstract Poster Presenter: Maja Ivanovic, MD (she/her/hers) – University of Chicago Medical Center
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1061: Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Location: Poster Hall
Abstract Poster Presenter: Chan Mi Lee – University Hospitals
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1062: Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Location: Poster Hall
Abstract Poster Presenter: Samuel Good, MD – University of California, Los Angeles
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1063: Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Location: Poster Hall
Abstract Poster Presenter: Shahin Jamal, MD, MSc (she/her/hers) – Vancouver Coastal Health
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1064: Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination
Location: Poster Hall
Abstract Poster Presenter: Ryan Wilson, MBBS – University of Limerick
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1065: Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Location: Poster Hall
Abstract Poster Presenter: Victoria V. Manyele, MD, MBBS – GEISINGER NORTH EAST
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1066: Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
Location: Poster Hall
Abstract Poster Presenter: Kelly Chun, PhD – Labcorp
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1067: A Comparison of Joint Involvement Patterns in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Rheumatoid Arthritis
Location: Poster Hall
Abstract Poster Presenter: Carlos Aude, BA – Johns Hopkins University School of Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1068: Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events
Location: Poster Hall
Abstract Poster Presenter: Maria del Carmen Lopez Gonzalez, II, MD (she/her/hers) – ISABIAL
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1069: Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)
Location: Poster Hall
Abstract Poster Presenter: Manush Sondhi, MD – LSU, Shreveport
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1070: Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon
Location: Poster Hall
Abstract Poster Presenter: Julien Seiller, MD, MSc – Hospices Civils de Lyon
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1071: No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)
Location: Poster Hall
Abstract Poster Presenter: Madeline O'Sullivan, MD, BS – University of Utah
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1072: Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Location: Poster Hall
Abstract Poster Presenter: Maria Suarez-Almazor, MD, PhD (she/her/hers) – MD Anderson Cancer Center
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1073: Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Location: Poster Hall
Abstract Poster Presenter: Mike Putman, MD, MSc – The Medical College of Wisconsin
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1074: Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Location: Poster Hall
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1075: Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Location: Poster Hall
Abstract Poster Presenter: Lourdes Gonzalez Arreola, MSc (she/her/hers) – Arthritis Research Canada
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1076: Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Location: Poster Hall
Abstract Poster Presenter: Olga Rusinovich, MD – Puerta de Hierro Majadahonda University Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1077: Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab
Location: Poster Hall
Abstract Poster Presenter: Pascal de Jong, MD, PhD – ErasmusMC
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1078: Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Location: Poster Hall
Abstract Poster Presenter: Yashswee KC, MD – Loyola University
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1079: Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements
Location: Poster Hall
Abstract Poster Presenter: Tawnie Braaten, MD – UNIVERSITY OF UTAH
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1080: Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study
Location: Poster Hall
Abstract Poster Presenter: Antoine Minier, MD (he/him/his) – Université de Sherbrooke
Hematologic- and oncologic-associated rheumatic syndromes
Monday, Nov 13th
9:00 AM – 11:00 AM PT
1081: Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial
Location: Poster Hall
Abstract Poster Presenter: Marthe Brun, MD – Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
4:00 PM – 5:30 PM PT
14T171: Abstracts: Immunological Complications of Medical Therapy (2509–2514)
Location: Room 25A-C
Abstract Moderator: Vibeke Strand, MD, FACP, MACR – Stanford University School of Medicine, Palo Alto CA
Abstract Moderator: Vanessa Smith, MD, PhD, -None- – Ghent University Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
4:00 PM – 4:10 PM PT
2509: Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
Location: Room 25A-C
Presenting Author: Kaitlin McCarter, MD – Brigham and Women's Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
4:15 PM – 4:25 PM PT
2510: Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1
Location: Room 25A-C
Presenting Author: Diane van der Woude, MD, PhD – Leiden University Medical Center
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
4:30 PM – 4:40 PM PT
2511: Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies
Location: Room 25A-C
Presenting Author: Christian Ammitzbøll, MD, PhD – Aarhus University Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
4:45 PM – 4:55 PM PT
2512: Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Location: Room 25A-C
Presenting Author: Jacques-eric GOTTENBERG, PhD – Hautepierre Hospital
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
5:00 PM – 5:10 PM PT
2513: Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Location: Room 25A-C
Presenting Author: Laura Cappelli, MD – Johns Hopkins School of Medicine
Hematologic- and oncologic-associated rheumatic syndromes
Tuesday, Nov 14th
5:15 PM – 5:25 PM PT
2514: Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Location: Room 25A-C
Presenting Author: Selene Rubino, MD – University of Utah
Hematologic- and oncologic-associated rheumatic syndromes